Karim Chamie1, Eric Ballon-Landa2, Timothy J Daskivich3, Jeffrey C Bassett3, Julie Lai4, Jan M Hanley4, Badrinath R Konety5, Mark S Litwin6, Christopher S Saigal7. 1. Health Services Research Group, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA. Electronic address: kchamie@mednet.ucla.edu. 2. Health Services Research Group, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA. 3. Health Services Research Group, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA. 4. RAND Corporation, Santa Monica, CA. 5. Department of Urology, University of Minnesota, Minneapolis, MN. 6. Health Services Research Group, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA; RAND Corporation, Santa Monica, CA; Department of Health Services, University of California Los Angeles, School of Public Health, Los Angeles, CA. 7. Health Services Research Group, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA; RAND Corporation, Santa Monica, CA.
Abstract
BACKGROUND: Multiple recurrences develop in patients with high-risk non-muscle-invasive bladder cancer. As neither the association of recurrences with survival nor the subsequent aggressive treatment in individuals with recurrent high-grade non-muscle-invasive bladder cancer has ever been quantified, we sought to determine whether the increasing number of recurrences is associated with higher subsequent treatment and mortality rates. METHODS: Using linked Surveillance, Epidemiology, and End Results-Medicare data, we identified subjects with recurrent high-grade, non-muscle-invasive disease diagnosed in 1992 to 2002 and followed up until 2007. Using competing-risks regression analyses, we quantified the incidence of radical cystectomy, radiotherapy, and systemic chemotherapy after each recurrence. We then performed a propensity-score adjusted competing-risks regression analysis to determine whether the increasing recurrences portend worse survival. RESULTS: Of 4,521 subjects, 2,694 (59.6%) had multiple recurrences within 2 years of diagnosis. Compared with patients who only had 1 recurrence, those with ≥ 4 recurrences were less likely to undergo radical cystectomy (hazard ratio [HR] = 0.73, 95% CI: 0.58-0.92), yet more likely to undergo radiotherapy (HR = 1.51, 95% CI: 1.23-1.85) and systemic chemotherapy (HR = 1.58, 95% CI: 1.15-2.18). For patients with ≥ 4 recurrences, only 25% were treated with curative intent. The 10-year cancer-specific mortality rates were 6.9%, 9.7%, 13.7%, and 15.7% for those with 1, 2, 3, and ≥ 4 recurrences, respectively. CONCLUSIONS: Only 25% of patients with high-risk non-muscle-invasive bladder cancer who experienced recurrences at least 4 times underwent radical cystectomy or radiotherapy. Despite portending worse outcomes, increasing recurrences do not necessarily translate into higher treatment rates.
BACKGROUND: Multiple recurrences develop in patients with high-risk non-muscle-invasive bladder cancer. As neither the association of recurrences with survival nor the subsequent aggressive treatment in individuals with recurrent high-grade non-muscle-invasive bladder cancer has ever been quantified, we sought to determine whether the increasing number of recurrences is associated with higher subsequent treatment and mortality rates. METHODS: Using linked Surveillance, Epidemiology, and End Results-Medicare data, we identified subjects with recurrent high-grade, non-muscle-invasive disease diagnosed in 1992 to 2002 and followed up until 2007. Using competing-risks regression analyses, we quantified the incidence of radical cystectomy, radiotherapy, and systemic chemotherapy after each recurrence. We then performed a propensity-score adjusted competing-risks regression analysis to determine whether the increasing recurrences portend worse survival. RESULTS: Of 4,521 subjects, 2,694 (59.6%) had multiple recurrences within 2 years of diagnosis. Compared with patients who only had 1 recurrence, those with ≥ 4 recurrences were less likely to undergo radical cystectomy (hazard ratio [HR] = 0.73, 95% CI: 0.58-0.92), yet more likely to undergo radiotherapy (HR = 1.51, 95% CI: 1.23-1.85) and systemic chemotherapy (HR = 1.58, 95% CI: 1.15-2.18). For patients with ≥ 4 recurrences, only 25% were treated with curative intent. The 10-year cancer-specific mortality rates were 6.9%, 9.7%, 13.7%, and 15.7% for those with 1, 2, 3, and ≥ 4 recurrences, respectively. CONCLUSIONS: Only 25% of patients with high-risk non-muscle-invasive bladder cancer who experienced recurrences at least 4 times underwent radical cystectomy or radiotherapy. Despite portending worse outcomes, increasing recurrences do not necessarily translate into higher treatment rates.
Authors: M Craig Hall; Sam S Chang; Guido Dalbagni; Raj Som Pruthi; John Derek Seigne; Eila Curlee Skinner; J Stuart Wolf; Paul F Schellhammer Journal: J Urol Date: 2007-12 Impact factor: 7.450
Authors: Karim Chamie; Christopher S Saigal; Julie Lai; Jan M Hanley; Claude M Setodji; Badrinath R Konety; Mark S Litwin Journal: Cancer Date: 2011-08-05 Impact factor: 6.860
Authors: Marko Babjuk; Maximilian Burger; Richard Zigeuner; Shahrokh F Shariat; Bas W G van Rhijn; Eva Compérat; Richard J Sylvester; Eero Kaasinen; Andreas Böhle; Joan Palou Redorta; Morgan Rouprêt Journal: Eur Urol Date: 2013-06-12 Impact factor: 20.096
Authors: Ganesh V Raj; Harry Herr; Angel M Serio; Sherri M Donat; Bernard H Bochner; Andrew J Vickers; Guido Dalbagni Journal: J Urol Date: 2007-04 Impact factor: 7.450
Authors: Ted A Skolarus; Zaojun Ye; Jeffrey S Montgomery; Alon Z Weizer; Khaled S Hafez; Cheryl T Lee; David C Miller; David P Wood; James E Montie; Brent K Hollenbeck Journal: Urology Date: 2011-10-11 Impact factor: 2.649
Authors: Erica H Lambert; Phillip M Pierorazio; Carl A Olsson; Mitchell C Benson; James M McKiernan; Steven Poon Journal: BJU Int Date: 2007-07 Impact factor: 5.588
Authors: Karim Chamie; Mark S Litwin; Jeffrey C Bassett; Timothy J Daskivich; Julie Lai; Jan M Hanley; Badrinath R Konety; Christopher S Saigal Journal: Cancer Date: 2013-06-04 Impact factor: 6.860
Authors: Frank N Burks; Alice B Liu; Ronald S Suh; Timothy G Schuster; Timothy Bradford; Don A Moylan; Peter M Knapp; Daniel S Murtagh; Rodney L Dunn; James E Montie; David C Miller Journal: J Urol Date: 2012-10-18 Impact factor: 7.450
Authors: Andrew T Lenis; Nicholas M Donin; Mark S Litwin; Christopher S Saigal; Julie Lai; Jan M Hanley; Badrinath R Konety; Karim Chamie Journal: Clin Genitourin Cancer Date: 2016-06-25 Impact factor: 2.872
Authors: C A Chai; W S Yeoh; R Rajandram; K P Aung; T A Ong; S Kuppusamy; A Nazran; K Kumaran; A H A Razack; J Y Teoh Journal: Front Surg Date: 2021-05-13
Authors: Stephen B Williams; Lauren E Howard; Meagan L Foster; Zachary Klaassen; Jan Sieluk; Amanda M De Hoedt; Stephen J Freedland Journal: JAMA Netw Open Date: 2021-03-01
Authors: Kelly K Bree; Yong Shan; Patrick J Hensley; Niyati Lobo; Chengrui Hu; Douglas S Tyler; Karim Chamie; Ashish M Kamat; Stephen B Williams Journal: JAMA Netw Open Date: 2022-03-01
Authors: Mihaela Georgiana Musat; Christina Soeun Kwon; Elizabeth Masters; Slaven Sikirica; Debduth B Pijush; Anna Forsythe Journal: Clinicoecon Outcomes Res Date: 2022-01-10